Related Experiment Video
Updated: Mar 22, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Statin drugs mitigate cellular inflammatory response after ST elevation myocardial infarction, but do not affect
Leili Pourafkari1, Ognjen Visnjevac2, Samad Ghaffari3
1Cardovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran ; State University of New York at Buffalo, Buffalo, NY, USA.
Insights
Statin use before ST-elevation myocardial infarction (STEMI) reduces post-infarction inflammation, indicated by lower white blood cell and neutrophil counts. This may help decrease complications like pump failure.
Area of Science:
- Cardiology
- Inflammation Research
- Pharmacology
Background:
- ST-elevation myocardial infarction (STEMI) is a critical cardiovascular event.
- Post-STEMI inflammation plays a significant role in patient outcomes.
- The impact of statins on post-STEMI inflammation requires further investigation.
Purpose of the Study:
- To investigate the role of statins in modulating inflammation following STEMI.
- To assess the effect of statin use on mortality and complications after STEMI.
Main Methods:
- A retrospective review of 404 patients with STEMI.
- Patients were categorized into STATIN and NOSTAT groups based on admission medication.
- Propensity score matching was used to compare outcomes between groups.
Main Results:
- The STATIN group exhibited lower neutrophil counts post-STEMI compared to the NOSTAT group.
- No significant difference in in-hospital mortality was observed.
- The incidence of pump failure was significantly lower in the STATIN group (5.6% vs. 15.7%, P < 0.01).
Conclusions:
- Pre-STEMI statin treatment mitigates the inflammatory response after myocardial infarction.
- Lower leukocyte and neutrophil counts were observed in patients treated with statins.
- Statin therapy may reduce the risk of pump failure post-STEMI.
Introduction:
The objective was to examine the role of statins in modulating post-STEMI inflammation and related mortality.
Methods:
A total of 404 patients with STEMI were reviewed. Demographics, comorbidities, laboratory values, and outcomes were collected. The patients were grouped as STATIN and NOSTAT based on the use of statin drugs at the time of admission. Ninety-seven patients were receiving statin drugs.
Results:
The patients in the STATIN group were more likely to be hypertensive (53.6%), diabetic (37.1%) and to have previous coronary revascularization (9.3%). Following propensity matching of 89 patients in STATIN group to an equal number of patients in NOSTAT controls had lower neutrophil count 7.8 (6.8-8.4) compared to those in the NOSTAT group 9.1 (7.9-10.1). Although there was no difference in-hospital mortality between the two groups, the incidence of pump failure was lower in the STATIN group (5.6% vs. 15.7%; P < 0.01).
Conclusion:
Statin treatment prior to STEMI mitigates the cellular inflammatory response after the myocardial infarction, as evidenced by lower leukocyte and neutrophil cell counts in the STATIN group.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:14Myocarditis III: Medical Management
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:27Coronary Artery Disease V: Interprofessional Care